Carl-Stephan Leonhardt

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Oliver Strobel · 21 shared papers, 2018–2026 · strength 4.40
   • Paper Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma - Authors' reply. DOI 10.1016/s1470-2045(26)00249-4↗
   • Paper Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. DOI 10.3791/68465↗
   • Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
2. Thomas P. Hank · 12 shared papers, 2022–2026 · strength 2.41
   • Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
   • Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
   • Paper Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. DOI 10.1016/j.esmoop.2023.102067↗
3. Ulla Klaiber · 9 shared papers, 2018–2026 · strength 1.78
   • Paper Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. DOI 10.3791/68465↗
   • Paper Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. DOI 10.1053/j.gastro.2024.05.028↗
   • Paper Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic … DOI 10.1097/js9.0000000000000792↗
4. Gerald W. Prager · 5 shared papers, 2023–2026 · strength 1.35
   • Paper Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma - Authors' reply. DOI 10.1016/s1470-2045(26)00249-4↗
   • Paper Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. DOI 10.1016/j.esmoop.2023.102067↗
   • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
5. Thilo Hackert · 7 shared papers, 2018–2026 · strength 1.31
   • Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
   • Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
   • Paper Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection o… DOI 10.1016/j.ejso.2022.08.003↗
6. Klaus Sahora · 5 shared papers, 2023–2025 · strength 1.16
   • Paper Standardized Approach to Superior Mesenteric Artery Resection for Locally Advanced Pancreatic Cancer. DOI 10.3791/68465↗
   • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
   • Paper Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic … DOI 10.1097/js9.0000000000000792↗
7. Markus Wolfgang Büchler · 6 shared papers, 2021–2023 · strength 0.94
   • Paper Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection o… DOI 10.1016/j.ejso.2022.08.003↗
   • Paper Oncological Outcome of Conversion Surgery After Preoperative Chemotherapy for Metastatic Pancreatic Cancer. DOI 10.1097/sla.0000000000005481↗
   • Paper Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. DOI 10.1245/s10434-022-12901-6↗
8. Martin Schindl · 4 shared papers, 2023–2025 · strength 0.79
   • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
   • Paper Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic … DOI 10.1097/js9.0000000000000792↗
   • Paper The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treat… DOI 10.1097/sla.0000000000005874↗
9. Andrew Louis Warshaw · 3 shared papers, 2023–2025 · strength 0.57
   • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
   • Paper The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treat… DOI 10.1097/sla.0000000000005874↗
   • Paper Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. DOI 10.1016/j.ejca.2023.113293↗
10. Motaz Qadan · 3 shared papers, 2023–2025 · strength 0.57
    • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
    • Paper The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treat… DOI 10.1097/sla.0000000000005874↗
    • Paper Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. DOI 10.1016/j.ejca.2023.113293↗
11. Keith D. Lillemoe · 3 shared papers, 2023–2025 · strength 0.57
    • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
    • Paper The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treat… DOI 10.1097/sla.0000000000005874↗
    • Paper Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. DOI 10.1016/j.ejca.2023.113293↗
12. Mohammed Al‐Saeedi · 2 shared papers, 2026 · strength 0.54
    • Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
    • Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
13. Martin Loos · 2 shared papers, 2026 · strength 0.54
    • Paper Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) After Pancreatic Cancer Res… DOI 10.1245/s10434-025-18698-4↗
    • Paper ASO Visual Abstract: Neoadjuvant Treatment is a Risk Factor for Clinically Relevant Chyle Leak (ISGPS Grade B/C) after … DOI 10.1245/s10434-025-18864-8↗
14. Caroline Sophie Verbeke · 2 shared papers, 2024 · strength 0.45
    • Paper Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. DOI 10.1053/j.gastro.2024.05.028↗
    • Paper Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic … DOI 10.1097/js9.0000000000000792↗
15. Solange Le Blanc · 3 shared papers, 2021–2024 · strength 0.44
    • Paper Prognostic Factors for Early Recurrence After Resection of Pancreatic Cancer: A Systematic Review and Meta-Analysis. DOI 10.1053/j.gastro.2024.05.028↗
    • Paper Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental h… DOI 10.1038/s41467-021-26059-4↗
    • Paper Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-der… DOI 10.1101/2021.08.26.457743↗
16. Jin Peng He · 2 shared papers, 2023 · strength 0.43
    • Paper ASO Author Reflections: Outcomes Support Aggressive Surgery for Early-Onset Pancreatic Cancer. DOI 10.1245/s10434-022-12948-5↗
    • Paper Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. DOI 10.1245/s10434-022-12901-6↗
17. Benedict Kinny‐Köster · 2 shared papers, 2023 · strength 0.43
    • Paper ASO Author Reflections: Outcomes Support Aggressive Surgery for Early-Onset Pancreatic Cancer. DOI 10.1245/s10434-022-12948-5↗
    • Paper Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. DOI 10.1245/s10434-022-12901-6↗
18. Carlos F. Fernandez-del Castillo · 2 shared papers, 2023–2025 · strength 0.39
    • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
    • Paper Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. DOI 10.1016/j.ejca.2023.113293↗
19. Christopher Lee Wolfgang · 2 shared papers, 2023–2026 · strength 0.35
    • Paper Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following p… DOI 10.1093/bjsopen/zrag057↗
    • Paper Resected Early-Onset Pancreatic Cancer: Practices and Outcomes in an International Dual-Center Study. DOI 10.1245/s10434-022-12901-6↗
20. Cristina Rosa Ferrone · 2 shared papers, 2023–2024 · strength 0.34
    • Paper The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treat… DOI 10.1097/sla.0000000000005874↗
    • Paper Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. DOI 10.1016/j.ejca.2023.113293↗
21. Jörg Kaiser · 2 shared papers, 2022–2023 · strength 0.33
    • Paper Presence of low-grade IPMN at the pancreatic transection margin does not have prognostic significance after resection o… DOI 10.1016/j.ejso.2022.08.003↗
    • Paper IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy. DOI 10.1016/j.ejso.2021.12.009↗
22. Michael Volkmar · 2 shared papers, 2021–2023 · strength 0.24
    • Paper Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic … DOI 10.1126/scitranslmed.adh9562↗
    • Paper Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-der… DOI 10.1101/2021.08.26.457743↗
23. Rienk Offringa · 2 shared papers, 2021–2023 · strength 0.24
    • Paper Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic … DOI 10.1126/scitranslmed.adh9562↗
    • Paper Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-der… DOI 10.1101/2021.08.26.457743↗
24. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.23
    • Paper Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal ad… DOI 10.1016/j.surg.2025.109647↗
25. Christian Conrad · 2 shared papers, 2021 · strength 0.22
    • Paper Single-cell analysis of patient-derived PDAC organoids reveals cell state heterogeneity and a conserved developmental h… DOI 10.1038/s41467-021-26059-4↗
    • Paper Deep molecular characterization linked to drug response profiling of pancreatic ductal adenocarcinoma using patient-der… DOI 10.1101/2021.08.26.457743↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.